Page 2349 - Williams Hematology ( PDFDrive )

2322 Part XII: Hemostasis and Thrombosis Chapter 135: Fibrinolysis and Thrombolysis 2323

279. Schott D, Dempfle CE, Beck P, et al: Therapy with a purified plasminogen concentrate 311. Corrigan JJ: Thrombosis and thromboembolism, in Hemorrhagic and Thrombotic Dis-
in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. ease in Childhood and Adolescence, pp 147–176. Churchill Livingstone, New York, 1985.
N Engl J Med 339:1679–1686, 1998. 312. Bonnar J, Daly L, Sheppard BL: Changes in the fibrinolytic system during pregnancy.
280. Robbins KC: Dysplasminogenemia. Prog Cardiovasc Dis 34:295–308, 1992. Semin Thromb Hemost 16:221–229, 1990.
281. Tsutsumi S, Saito T, Sakata T, et al: Genetic diagnosis of dysplasminogenemia: Detec- 313. Brenner B: Haemostatic changes in pregnancy. Thromb Res 114:409–414, 2004.
tion of an Ala601-Thr mutation in 118 out of 125 families and identification of a new 314. Bremme KA: Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 16:153–
Asp676-Asn mutation. Thromb Haemost 76:135–138, 1996. 168, 2003.
282. Lijnen HR, Collen D: Congenital and acquired deficiencies of components of the 315. Hellgren M: Hemostasis during pregnancy and puerperium. Haemostasis 26:244–247,
fibrinolytic system and their relationship to bleeding or thrombosis. Fibrinolysis 3:67– 1996.
77, 1989. 316. Schjetlein R, Haugen G, Wisloff F: Markers of intravascular coagulation and fibrinolysis
283. Rakoczi I, Chamone D, Collen D, Verstraete M: Prediction of postoperative leg vein in preeclampsia: Association with intrauterine growth retardation. Acta Obstet Gynecol
thrombosis in gynaecological patients. Lancet 1:509–510, 1978. Scand 76:541–546, 1997.
284. Nilsson IM, Ljungner H, Tengborn L: Two different mechanisms in patients with venous 317. SantAna Dusse LM, Cooper AJ, Lwaleed BA: Thrombin activatable fibrinolysis inhibi-
thrombosis and defective fibrinolysis: Low concentrations of plasminogen activator or tor (TAFI): A role in pre-eclampsia? Clin Chim Acta 378:1–6, 2007.
increased concentration of plasminogen activator inhibitor. Br Med J 290:1453–1456, 318. Hajjar KA, Francis CW: Fibrinolysis and thrombolysis, Williams Hematology, 7th ed,
1985. edited by K Kaushansky, MA Lichtman, E Beutler, TJ Kipps, U Seligsohn, JT Prchal,
285. Meltzer ME, Doggen CJ, De Groot PG, et al: The impact of the fibrinolytic system on pp 2089–2115. McGraw-Hill, New York, 2006.
the risk of venous and arterial thrombosis. Semin Thromb Hemost 35:469–477, 2009. 319. Sherry S, Fletcher AP, Alkjaersig N: Fibrinolysis and fibrinolytic activity in man. Physiol
286. Meltzer ME, Doggen CJ, De Groot PG, et al: Reduced plasma fibrinolytic capacity as Rev 39:343–382, 1959.
a potential risk factor for a first myocardial infarction in young men. Br J Haematol 320. Adelman B, Michelson AD, Loscalzo J, et al: Plasmin effect on platelet glycoprotein
145:121–127, 2009. Ib-von Willebrand factor interactions. Blood 65:32–40, 1985.
287. Hamsten A, Wiman B, De Faire U, Blomback M: Increased plasma levels of a rapid 321. Loscalzo J, Vaughan DE: Tissue plasminogen activator promotes platelet disaggregation
inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. in plasma. J Clin Invest 79:1749–1755, 1987.
N Engl J Med 313:1557–1563, 1985. 322. Rudd MA, George D, Amarante P, et al: Temporal effects of thrombolytic agents on
288. Paramo JA, Alfaro MJ, Rocha E: Postoperative changes in the plasmatic levels of platelet function in vivo and their modulation by prostaglandins. Circ Res 67:1175–
tissue-type plasminogen activator and its fast-acting inhibitor: Relationship to deep 1181, 1990.
vein thrombosis and influence of prophylaxis. Thromb Haemost 54:713–716, 1985. 323. Go AS, Mozaffarian D, Roger VL, et al: Executive summary: Heart disease and stroke
289. Juhan-Vague I, Roul C, Alessi MC, et al: Increased plasminogen activator inhibitor statistics—2014 update: A report from the American Heart Association. Circulation
activity in non-insulin dependent diabetic patients: Relationship with plasma insulin. 129:399–410, 2014.
Thromb Haemost 61:370–373, 1989. 324. Abe T, Kazama M, Naito I, et al: Clinical evaluation for efficacy of tissue culture urok-
290. Francis CW: Plasminogen activator inhibitor-1 levels and polymorphisms: Association inase (TCUK) on cerebral thrombosis by means of multicenter double blind study.
with venous thromboembolism. Arch Pathol Lab Med 126:1401–1404, 2002. Blood Vessels 12:321–341, 1981.
291. Tsantes AE, Nikolopoulos GK, Bagos PG, et al: The effect of the plasminogen activator 325. Abe T, Kazama M, Naito I, et al: Clinical effect of urokinase (60,000 units/day) on cere-
inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 122:736–742, bral infarction comparative study by means of multiple center double blind test. Blood
2008. Vessels 12:342–358, 1981.
292. Juhan-Vague I, Alessi MC, Joly P, et al: Plasma plasminogen activator inhibitor-1 in 326. Atarashi J, Otomo E, Araki G, et al: Clinical utility of urokinase in the treatment of
angina pectoris: Influence of plasma insulin and acute-phase response. Arteriosclerosis acute stage of cerebral thrombosis: Multi-center double-blind study in comparison with
9:362–367, 1989. placebo. Clin Eval 13:659–709, 1985.
293. Stump DC, Taylor FB, Nesheim ME, et al: Pathologic fibrinolysis as a cause of clinical 327. del Zoppo GJ, Ferbert A, Otis S, et al: Local intra-arterial fibrinolytic therapy in acute
bleeding. Semin Thromb Hemost 16:260–273, 1990. carotid territory stroke. A pilot study. Stroke 19:307–313, 1988.
294. Saito H: Alpha-2-plasmin inhibitor and its deficiency states. J Lab Clin Med 112:671– 328. Fletcher AP, Alkjaersig N, Lewis M, et al: A pilot study of urokinase therapy in cerebral
678, 1988. infarction. Stroke 7:135–142, 1976.
295. Gresele P, Binetti BM, Branca G, et al: TAFI deficiency in liver cirrhosis: Relation with 329. Hacke W, Zeumer H, Ferbert A, et al: Intra-arterial thrombolytic therapy improves out-
plasma fibrinolysis and survival. Thromb Res 121:763–768, 2008. come in patients with acute vertebrobasilar occlusive disease. Stroke 19:1216–1222, 1988.
296. Stein E, McMahon B, Kwaan H, et al: The coagulopathy of acute promyelocytic leu- 330. Hanaway J, Torack R, Fletcher AP, Landau WM: Intracranial bleeding associated with
kaemia revisited. Best Pract Res Clin Haematol 22:152–163, 2009. urokinase therapy for acute ischemic hemispheral stroke. Stroke 7:143–146, 1976.
297. Fay WP, Shapiro AD, Shih JL, et al: Brief report: Complete deficiency of plasminogen- 331. Matsumoto K, Satoh K: Topical Intraarterial Urokinase Infusion for Acute Stroke.
activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 327:1729–1733, Springer-Verlag, Heidelberg, 1991.
1992. 332. Meyer JS, Gilroy J, Barnhart MI, Johnson JF: Therapeutic thrombolysis in cerebral
298. Suarez CR, Walenga J, Mangogna LC, Fareed J: Neonatal and maternal fibrinolysis: thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid
Activation at time of birth. Am J Hematol 19:365–372, 1985. and middle cerebral arterial occlusion. Neurology 13:927–937, 1963.
299. Albisetti M: The fibrinolytic system in children. Semin Thromb Hemost 29(4):339–348, 333. Meyer JS, Gilroy J, Barnhart MI, Johnson JF: Anticoagulants plus streptokinase therapy
2003. in progressive stroke. JAMA 189:373, 1964.
300. Summaria L: Comparison of human normal, full-term, fetal and adult plasminogen by 334. Mori E, Tabuchi M, Yoshida T, Yamadori A: Intracarotid urokinase with thromboem-
physical and clinical analyses. Haemostasis 19:266–273, 1989. bolic occlusion of the middle cerebral artery. Stroke 19:802–812, 1988.
301. Edelberg JM, Enghild JJ, Pizzo SV, Gonzales-Gronow M: Neonatal plasminogen dis- 335. Mori E: Fibrinolytic Recanalization Therapy in Acute Cerebrovascular Thromboembo-
plays altered cell surface binding and activation kinetics: Correlation with increased lism. Springer-Verlag, Heidelberg, 1991.
glycosylation of the protein. J Clin Invest 86:107–112, 1990. 336. Otomo E, Araki G, Itoh E, et al: Clinical efficacy of urokinase in the treatment of cere-
302. Andrew M, Brooker L, Leaker M, et al: Fibrin clot lysis by thrombolytic agents is bral thrombosis. Clin Eval 13:711–751, 1985.
impaired in newborns due to a low plasminogen concentration. Thromb Haemost 337. Theron J, Courtheoux P, Casasco A, et al: Local intraarterial fibrinolysis in the carotid
68:325–330, 1992. territory. AJNR Am J Neuroradiol 10:753–765, 1989.
303. Corrigan JJ, Sleeth JJ, Jeter MA, Lox CD: Newborn’s fibrinolytic mechanism: Compo- 338. Zeumer H, Freitag HJ, Grzyska U, Neunzig HP: Local intra-arterial fibrinolysis in acute
nents and plasmin generation. Am J Hematol 32:273–278, 1989. vertebrobasilar occlusion. Technical developments and recent results. Neuroradiology
304. Corrigan JJ, Jeter MA: Histidine-rich glycoprotein and plasminogen plasma levels in 31(4):336–340, 1989.
term and preterm newborns. Am J Dis Child 144:825–828, 1990. 339. Zeumer H, Freitag HJ, Zanella F, et al: Local intra-arterial fibrinolytic therapy in
305. Parmar N, Albisetti M, Berry LR, Chan AK: The fibrinolytic system in newborns and patients with stroke: Urokinase versus recombinant tissue plasminogen activator
children. Clin Lab 52:115–124, 2006. (r-TPA). Neuroradiology 35:159–162, 1993.
306. Corrigan JJ, Jeter MA: Tissue-type plasminogen activator, plasminogen activator inhib- 340. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neuro-
itor, and histidine-rich glycoprotein in stressed human newborns. Pediatrics 89:43–46, logical Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333:1581–1587, 1995.
1992. 341. Hacke W, Kaste M, Fieschi C, et al: Intravenous thrombolysis with recombinant tissue
307. Brus F, Van Oeveren W, Okkern A, Oetomo SB: Activation of the plasma clotting, plasminogen activator for acute hemispheric stroke. The European Cooperative Acute
fibrinolytic, and kinin-kallikrein system in preterm infants with severe idiopathic respi- Stroke Study (ECASS). JAMA 274(13):1017–1025, 1995.
ratory distress syndrome. Pediatr Res 36:647–653, 1994. 342. Hacke W, Kaste M, Fieschi C, et al: Randomised double-blind placebo-controlled trial
308. Cederholm-Williams SA, Spencer JA, Wilkerson AR: Plasma levels of selected haemo- of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS
static factors in newborn babies. Thromb Res 23:555–558, 1981. II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352:1245–
309. Andrew M, Paes B, Milner R, et al: Development of the human coagulation system in 1251, 1998.
the full-term infant. Blood 70:165–172, 1987. 343. Clark WM, Wissman S, Albers GW, et al: Recombinant tissue-type plasminogen acti-
310. Andrew M, Massicotte-Nolan PM, Karpatkin M: Plasma protease inhibitors in prema- vator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS
ture infants: Influence of gestational age, postnatal age, and health status. Proc Soc Exp Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterven-
Biol Med 173:495–500, 1983. tional Therapy in Ischemic Stroke. JAMA 282:2019–2026, 1999.

Kaushansky_chapter 135_p2303-2326.indd 2323 9/18/15 5:14 PM